Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey

被引：0
|
作者：
Alexander Keenan
Dee Lin
Jason Shepherd
Hollie Bailey
Carmela Benson
Sophie Meakin
机构：
[1] Janssen Global Services,
[2] LLC,undefined
[3] Janssen Scientific Affairs,undefined
[4] LLC,undefined
[5] Adelphi Real World,undefined
来源：
BMC Psychiatry | / 22卷
关键词：
Schizophrenia; Long-acting injectable; Antipsychotics; Patient-physician communication; Prescribing drivers; Discordance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 34 条
  • [11] Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey
    Zhdanava, Maryia
    Starr, H. Lynn
    Totev, Todor, I
    Lefebvre, Patrick
    Shah, Aditi
    Sheng, Kristy
    Pilon, Dominic
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 2003 - 2019
  • [12] Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
    Fitzgerald, Heather M.
    Shepherd, Jason
    Bailey, Hollie
    Berry, Mia
    Wright, Jack
    Chen, Maxine
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 3215 - 3228
  • [13] Clinical benefit of second-generation long-acting injectable antipsychotics in preventing re-hospitalization in patients with schizophrenia: A real-world study in Japan
    Kasahara-Kiritani, Mami
    Saga, Yosuke
    Wakamatsu, Akihide
    Wu, David Bin-Chia
    Tsai, I. -Ching
    ASIAN JOURNAL OF PSYCHIATRY, 2023, 86
  • [14] DO LONG-ACTING INJECTABLE ANTIPSYCHOTICS (LAIS) LOWER HOSPITAL UTILIZATION AND DELIVER SUPERIOR ECONOMIC OUTCOMES IN SCHIZOPHRENIA (SCZ)? A SYSTEMATIC REVIEW OF REAL-WORLD EVIDENCE (RWE)
    Aslam, A.
    Nayak, R.
    VALUE IN HEALTH, 2022, 25 (07) : S599 - S599
  • [15] Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
    John Lauriello
    Peter J. Weiden
    Carole D. Gleeson
    Ankit Shah
    Luke Boulanger
    Krutika Jariwala-Parikh
    Elizabeth Hedgeman
    Amy K. O’Sullivan
    CNS Drugs, 2021, 35 : 1123 - 1135
  • [16] Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
    Lauriello, John
    Weiden, Peter J.
    Gleeson, Carole D.
    Shah, Ankit
    Boulanger, Luke
    Jariwala-Parikh, Krutika
    Hedgeman, Elizabeth
    O'Sullivan, Amy K.
    CNS DRUGS, 2021, 35 (10) : 1123 - 1135
  • [17] Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis
    Lin, Dee
    Thompson-Leduc, Philippe
    Ghelerter, Isabelle
    Nguyen, Ha
    Lafeuille, Marie-Helene
    Benson, Carmela
    Mavros, Panagiotis
    Lefebvre, Patrick
    CNS DRUGS, 2021, 35 (05) : 469 - 481
  • [18] Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis
    Dee Lin
    Philippe Thompson-Leduc
    Isabelle Ghelerter
    Ha Nguyen
    Marie-Hélène Lafeuille
    Carmela Benson
    Panagiotis Mavros
    Patrick Lefebvre
    CNS Drugs, 2021, 35 : 469 - 481
  • [19] Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs)
    Brugnoli, Roberto v
    Rapinesi, Chiara
    Kotzalidis, Georgios D.
    Marcellusi, Andrea
    Mennini, Francesco S.
    De Filippis, Sergio
    Carrus, Dario
    Ballerini, Andrea
    Francomano, Antonio
    Ducci, Giuseppe
    Del Casale, Antonio
    Girardi, Paolo
    RIVISTA DI PSICHIATRIA, 2016, 51 (02) : 47 - 59
  • [20] Correction to: Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis
    Dee Lin
    Philippe Thompson-Leduc
    Isabelle Ghelerter
    Ha Nguyen
    Marie-Hélène Lafeuille
    Carmela Benson
    Panagiotis Mavros
    Patrick Lefebvre
    CNS Drugs, 2021, 35 : 923 - 923
1234